Opeyemi A. Jegede

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

David A. Braun, Yue Hou, Ziad Bakouny et al. · Nature Medicine · 2020 · 1K citations · Full text

Medicine, Immunology, Oncology +16

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation

Andres Correa, Opeyemi A. Jegede, Naomi B. Haas et al. · Journal of Clinical Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Urology +17

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Jean‐Christophe Pignon, Opeyemi A. Jegede, Sachet A. Shukla et al. · Clinical Cancer Research · 2019 · 121 citations · Full text

Medicine, Immunology, Oncology +17

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

Rupal S. Bhatt, Abdulla Berjis, Julie C. Konge et al. · Cancer Immunology Research · 2020 · 113 citations · Full text

Life Sciences, Immunology, Oncology +17

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma

Miriam Ficial, Opeyemi A. Jegede, Miriam Sant’Angelo et al. · Clinical Cancer Research · 2020 · 83 citations · Full text

Life Sciences, Immunology, Oncology +17